Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced <br /> esophageal or gastric cancer.<br />
Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced
esophageal or gastric cancer.
The efficacy was not particularly notable among the 21 patients on this study, Karasic notes. Five of the patients achieved stable disease for greater than 2 months and 2 of the patients achieved stable disease for greater than 4 months. The patient with the longest duration of response was the only patient who continued trastuzumab (Herceptin) on study.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Pembrolizumab/Trastuzumab/Chemo Enhances Survival in HER2+ Gastric Cancer
May 1st 2024The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Read More